Adult Growth Hormone Deficiency is typically caused by damage to the hypothalamus or pituitary gland due to tumors, surgery, cranial radiation, or traumatic brain injury.3
More than 50,000 patients are diagnosed with AGHD in the United States, with 6,000 new cases reported yearly.4
Growth hormone is produced by the pituitary gland and secreted in pulses, so random measurements of growth hormone levels in the blood are not useful for establishing a diagnosis of AGHD.5
Growth hormone stimulation testing provokes the pituitary gland to release levels of growth hormone above normal levels to determine the maximum growth hormone level in a patient suspected of having AGHD.5
|Growth hormone is critical for adults to maintain healthy tissue and organ function.6|
|If left undiagnosed, AGHD may lead to increased risk for premature mortality, significant morbidity, and multiple signs and symptoms which include: an increase in body fat, a decrease in muscle mass, weakness and fatigue, osteoporosis, an increased rate of fractures, dyslipidemia, and cardiovascular disease.3,4,7|
|Patients may also experience depression, anxiety, and isolation due to psychological impairments associated with AGHD such as impaired concentration and memory loss, dissatisfaction with body image, and decreased quality of life.8|
|Treatment with growth hormone improves both the physical and psychological symptoms for patients with AGHD, improving quality of life.9|
Macrilen™ (macimorelin), an oral ghrelin agonist, is the first and only FDA-approved oral test indicated for the diagnosis of Adult Growth Hormone Deficiency.
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to Macrilen™. Click here for more details.
Endocrine Society Clinical Practice Guidelines recommend suspected AGHD be tested and if positive, treated with recombinant exogenous growth hormone.10
What is Macrilen?
Macrilen (pronounced ma-kri-len) (macimorelin) is a prescription oral solution that is used to test for adult growth hormone deficiency (AGHD).
What should you know about Macrilen?
What are the most common side effects with Macrilen?
The most common side effects were changed sense of taste, dizziness, headache, fatigue, nausea, hunger, diarrhea, upper respiratory tract infection, feeling hot, excessive sweating, sore nose and throat, and decreased heart rate.
These are not all of the possible side effects of Macrilen. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.
© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
Macrilen™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V14 08/2018